On this episode of Stock Movers:
- Lockheed Martin (LMT) shares are higher with defense stocks potentially taking a hit from tariff clarity. India is reconsidering US weapons purchases. It comes as Swiss politicians are seeking to cancel an order of F-35A fighter jets from Lockheed Martin Corp after President Donald Trump imposed a 39% tariff rate on the country. The moves are in response to US tariff policy.
- Monster Beverage (MNST) is the biggest volume mover in the premarket and is trading higher as sales surpassed expectations as more people consumed energy drinks. “Increased household penetration and per capita consumption of energy drinks remain positive trends for the category,” said Hilton Schlosberg, Monster’s Chief Executive Officer in a statement Thursday.
- Gilead Sciences (GILD) shares are higher after it lifted its full-year outlook after strong HIV drug sales in the second quarter helped revenue and earnings modestly beat analyst expectations. Gilead’s HIV franchise continues to be a source of steady growth, with the HIV pill Biktarvy accounting for about half of the company’s revenue in the second quarter, and sales of the drug rose 9% to $3.53 billion.

On this episode of Stock Movers: - Lockheed Martin (LMT) shares are higher with defense stocks potentially taking a hit from tariff clarity. India is reconsidering US weapons purchases. It comes as Swiss politicians are seeking to cancel an order of F-35A fighter jets from Lockheed Martin Corp after President Donald Trump imposed a 39% tariff rate on the country. The moves are in response to US tariff policy. - Monster Beverage (MNST) is the biggest volume mover in the premarket and is trading higher as sales surpassed expectations as more people consumed energy drinks. &ldquo;Increased household penetration and per capita consumption of energy drinks remain positive trends for the category,&rdquo; said Hilton Schlosberg, Monster&rsquo;s Chief Executive Officer in a statement Thursday. - Gilead Sciences (GILD) shares are higher after it lifted its full-year outlook after strong HIV drug sales in the second quarter helped revenue and earnings modestly beat analyst expectations. Gilead&rsquo;s HIV franchise continues to be a source of steady growth, with the HIV pill Biktarvy accounting for about half of the company&rsquo;s revenue in the second quarter, and sales of the drug rose 9% to $3.53 billion.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Defense Stocks and Tariffs; Monster Jumps; Gilead Higher on Earnings

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/71040222-d298-418b-ab2f-b33300b63ab3/transcript

Advertisement